Three trends in the antibody-drug conjugate (ADC) market
Drug Discovery World
JUNE 1, 2023
Roberto Iacone, CEO at Alentis Therapeutics, said: “There are huge unmet needs in organ fibrosis and cancer, and this funding enables us to continue with the important work we’re doing in the CLDN1 space and generate clinical data from both our programs.
Let's personalize your content